Kraig Biocraft Laboratories, Inc. announced this morning that Dr. Fraserâ€™s team has “made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm.”
“In the Company’s view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers,” stated Kraig’s CEO, Kim K. Thompson. “Dr. Fraser’s report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization,” continued Thompson.
“We believe that we are the only people who have this capability at this time.” Dr. Fraser added.
Dr. Fraser’s team of research scientists, working within University of Notre Dame laboratories, has made several significant advancements over the last four or five months. This most recent announcement follows shortly after the company’s report that it had performed approximately five thousand genetic insertions, and that it had achieved the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets.
Site specific genetic recombination allows for the genetic targeting of a specific location on a specific chromosome. This ability is potentially vital to the company’s work because of the strong influence of what geneticists call “location effects.” These effects do not result from the coding of a specific gene, but from the location of that gene on a specific chromosome.
Let us hear your thoughts: Kraig Biocraft Laboratories, Inc. Message Board